355 related articles for article (PubMed ID: 23091106)
1. Risks of less common cancers in proven mutation carriers with lynch syndrome.
Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
[TBL] [Abstract][Full Text] [Related]
2. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
3. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.
Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444
[TBL] [Abstract][Full Text] [Related]
4. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
[TBL] [Abstract][Full Text] [Related]
5. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
[TBL] [Abstract][Full Text] [Related]
6. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
[TBL] [Abstract][Full Text] [Related]
7. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
8. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
[TBL] [Abstract][Full Text] [Related]
9. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
Boilesen AE; Bisgaard ML; Bernstein I
Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
[TBL] [Abstract][Full Text] [Related]
10. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
[TBL] [Abstract][Full Text] [Related]
11. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
[TBL] [Abstract][Full Text] [Related]
12. Evidence for breast cancer as an integral part of Lynch syndrome.
Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
[TBL] [Abstract][Full Text] [Related]
13. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
14. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
[TBL] [Abstract][Full Text] [Related]
15. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
[TBL] [Abstract][Full Text] [Related]
16. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.
Ryan NAJ; Morris J; Green K; Lalloo F; Woodward ER; Hill J; Crosbie EJ; Evans DG
JAMA Oncol; 2017 Dec; 3(12):1702-1706. PubMed ID: 28772289
[TBL] [Abstract][Full Text] [Related]
17. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
[TBL] [Abstract][Full Text] [Related]
19. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.
Guindalini RS; Win AK; Gulden C; Lindor NM; Newcomb PA; Haile RW; Raymond V; Stoffel E; Hall M; Llor X; Ukaegbu CI; Solomon I; Weitzel J; Kalady M; Blanco A; Terdiman J; Shuttlesworth GA; Lynch PM; Hampel H; Lynch HT; Jenkins MA; Olopade OI; Kupfer SS
Gastroenterology; 2015 Nov; 149(6):1446-53. PubMed ID: 26248088
[TBL] [Abstract][Full Text] [Related]
20. Risk of cancer in cases of suspected lynch syndrome without germline mutation.
Rodríguez-Soler M; Pérez-Carbonell L; Guarinos C; Zapater P; Castillejo A; Barberá VM; Juárez M; Bessa X; Xicola RM; Clofent J; Bujanda L; Balaguer F; Reñé JM; de-Castro L; Marín-Gabriel JC; Lanas A; Cubiella J; Nicolás-Pérez D; Brea-Fernández A; Castellví-Bel S; Alenda C; Ruiz-Ponte C; Carracedo A; Castells A; Andreu M; Llor X; Soto JL; Payá A; Jover R
Gastroenterology; 2013 May; 144(5):926-932.e1; quiz e13-4. PubMed ID: 23354017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
